Status:
TERMINATED
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
HIV Infections
Giant Lymph Node Hyperplasia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy. Efficac...
Detailed Description
HIV-related multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterized by lymphadenopathy with angiofollicular hyperplasia and plasma cell infiltration, associated with KSHV/...
Eligibility Criteria
Inclusion
- Confirmed multicentric Castleman disease, with dependence on vinblastine or VP16 for at least 3 months, whenever they have been splenectomized
- At least one Castleman crisis since onset of chemotherapy
- Ongoing highly active antiretroviral therapy (HAART) for at least 3 months
- No threshold of CD4 cell count and HIV-RNA
- Signed written informed consent
Exclusion
- Prior treatment with rituximab
- Evolutive lymphoma or Kaposi's sarcoma needing treatment
- Absence of effective contraception
- Pregnancy
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00127569
Start Date
May 1 2003
End Date
January 1 2006
Last Update
January 12 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.